LifeTech Scientific Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

LifeTech Scientific şirketinin toplam hissedar öz sermayesi CN¥3.4B ve toplam borcu CN¥99.0M olup, bu da borç-öz sermaye oranını 2.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥4.8B ve CN¥1.4B dir. LifeTech Scientific 'in FAVÖK'ü CN¥262.5M faiz karşılama oranı -16 dur. Şirketin CN¥1.0B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

2.9%

Borç/özkaynak oranı

CN¥99.00m

Borç

Faiz karşılama oranı	-16x
Nakit	CN¥1.04b
Eşitlik	CN¥3.39b
Toplam yükümlülükler	CN¥1.43b
Toplam varlıklar	CN¥4.82b

Son finansal sağlık güncellemeleri

Is LifeTech Scientific (HKG:1302) A Risky Investment?

Nov 20

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Mar 31

Recent updates

LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump

Oct 02

Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E

Jul 05

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

Apr 25

What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You

Dec 25

Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled

Nov 28

At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?

Nov 03

Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return

Oct 14

There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital

Jul 15

Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?

Jun 30

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

Jun 15

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Apr 03

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Mar 15

Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?

Jan 22

Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital

Dec 19

Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today

Dec 06

Is LifeTech Scientific (HKG:1302) A Risky Investment?

Nov 20

An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued

Oct 12

The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence

Sep 13

Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?

Aug 28

What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?

Aug 13

LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business

Jun 08

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

May 26

Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?

May 11

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Mar 31

Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%

Feb 21

Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?

Jan 26

Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 13

Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?

Nov 25

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1302 'nin kısa vadeli varlıkları ( CN¥2.2B ) kısa vadeli yükümlülüklerini ( CN¥826.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1302 şirketinin kısa vadeli varlıkları ( CN¥2.2B ) uzun vadeli yükümlülüklerini ( CN¥602.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1302 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 1302 'nin borç/öz sermaye oranı son 5 yılda 22.7% seviyesinden 2.9% seviyesine düştü.

Borç Kapsamı: 1302 'nin borcu işletme nakit akışı ( 300.6% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 1302 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Bilanço

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/15 14:30
Gün Sonu Hisse Fiyatı	2025/02/14 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

LifeTech Scientific Corporation 5 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yuan Gao	China International Capital Corporation Limited
Hanqing Zhu	Guosen Securities Co., Ltd.
Yidong Zhang	Industrial Securities Co. Ltd.

LifeTech Scientific Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is LifeTech Scientific (HKG:1302) A Risky Investment?

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Recent updates

Lifetech Scientific Corporation Announces the Ankura Aortic Stent Graft System Obtains Official Registration Approval from the China National Medical Products Administration

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 32%

Investor sentiment deteriorates as stock falls 20%

LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: CN¥0.046 (vs CN¥0.049 in 1H 2023)

New minor risk - Profit margin trend

LifeTech Scientific Corporation to Report First Half, 2024 Results on Aug 30, 2024

Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E

LifeTech Scientific Corporation Announces One-Year Follow-Up Results of Phase II Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

LifeTech Scientific Corporation, Annual General Meeting, May 27, 2024

Full year 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.077 in FY 2022)

LifeTech Scientific Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You

Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled

At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?

First half 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 in 1H 2022)

Epione Surgical Navigation System Obtained Official Registration Approval by the China NMPA

Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)

LifeTech Scientific Corporation to Report First Half, 2023 Results on Aug 30, 2023

Is There Now An Opportunity In LifeTech Scientific Corporation (HKG:1302)?

Lifetech Scientific Corporation Announces Enrollment in the Phase Iii Clinical Study of Ibs®? Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)

Full year 2022 earnings released: EPS: CN¥0.077 (vs CN¥0.068 in FY 2021)

Investor sentiment improved over the past week

LifeTech Scientific Corporation Announces Enrollment in the China Randomized Controlled Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

Insufficient new directors

Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return

LifeTech Scientific Corporation Announces FDA Approval Investigator-Initiated Pre-Market Clinical Trial of Lambre Plus Laa Closure System Obtained Medical Insurance Coverage in the US

First half 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.047 in 1H 2021)

LifeTech Scientific Corporation to Report Q2, 2022 Results on Aug 30, 2022

There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital

Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

Insufficient new directors

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Full year 2021 earnings: EPS and revenues miss analyst expectations

LifeTech Scientific Corporation, Annual General Meeting, May 27, 2022

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?

Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital

Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today

Lifetech Scientific Corporation Announces YuranosTM Abdominal Aortic Stent Graft System Obtained Registration Approval from the China NMPA

Is LifeTech Scientific (HKG:1302) A Risky Investment?

An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued

The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence

First half 2021 earnings released: EPS CN¥0.047 (vs CN¥0.023 in 1H 2020)

Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?

What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?

Investor sentiment deteriorated over the past week

LifeTech Scientific Corporation Announces Grant of Medical Device Registration Certificate in Malaysia for Its Self-Developed Ibs Angeltm Iron Bioresorbable Scaffold System

LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?

Investor sentiment improved over the past week

Non-Executive Director has left the company

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019)

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019)

LifeTech Scientific Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: HK$3.62

Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%

Lifetech Scientific Corporation Announces Admission to Special Examination and Approval Procedure for Innovative Medical Devices in Respect of Artery Stent Graft System

Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?

New 90-day high: HK$5.46

New 90-day high: HK$4.43

Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?

Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?

Gl Trade Investment III L.P. and Gao Ling Fund, L.P., a fund managed by Hillhouse Capital Management, Ltd. acquired 10.67% stake in LifeTech Scientific Corporation (SEHK:1302) from Central Huijin Investment Ltd.

Market bids up stock over the past week

New 90-day high: HK$2.99